Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

A company that has Donald Trump Jr. on its board touted in a press release a new “initiative” to help pharmaceutical ...

The UK’s voluntary scheme for branded medicines pricing, access and growth (known as VPAG) makes sure that the NHS does not ...

In May, Pfizer CEO Dr. Albert Bourla defended previous comments HHS officials made about mRNA vaccines. 2 At the time, he called mRNA vaccines the most utilized vaccines in human history. He cited the ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Tánaiste Simon Harris has said the introduction of the new US tariff on EU goods provides "some degree of certainty" to businesses.

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

Pfizer CEO Albert Bourla said his company is in “very active discussions” over Trump’s request concerning most-favoured-nation pricing, according to news website FiercePharma. Bourla said he had ...